Table 1.
Clinical trials concerning metabolic inhibitors in pancreatic cancer
| Identifier | Recruitment status | Intervention | Study phase | Cancer stage |
|---|---|---|---|---|
| Target: Glucose metabolism | ||||
| NCT00096707 | Completed | 2-deoxy-d-glucose (2DG) | I | Locally advanced or metastatic solid malignancy |
| NCT04542291 | Recruiting | Dapagliflozin | I | Metastatic or locally advanced pancreatic cancer |
| NCT01835041 | Active, not recruiting | CPI-613/Modified FOLFIRINOX | I | Metastatic pancreatic adenocarcinoma |
| NCT03435289 | Unknown | CPI-613/Gemcitabine/Nab-paclitaxel | I | Locally advanced or metastatic pancreatic cancer |
| NCT03699319 | Recruiting | CPI-613 /Modified FOLFIRINOX | I/II | Locally advanced (including unresectable or borderline resectable) pancreatic cancer |
| NCT03504423 | Active, not recruiting | CPI-613 /mFolfirinox/Folfirinox | III | Metastatic stage IV adeno-carcinoma of the pancreas |
| NCT01839981 | Completed | CPI-613 | I | Locally advanced or metastatic pancreatic adenocarcinoma |
| NCT03854110 | Recruiting | GP-2250 | I/II | Advanced unresectable or metastatic pancreatic adenocarcinoma |
| Target: Lipid metabolism | ||||
| NCT02201381 | Not yet recruiting | Metformin/Atorva-statin/Doxycycline/Mebendazole | III | Any cancer type and stage |
| NCT00944463 | Completed | Gemcitabine/Simvastatin | II | Metastatic or unresectable pancreatic adenocarcinoma |
| NCT03889795 | Recruiting | Simvastatin/Metformin/Digoxin | I | Advanced pancreatic cancer/Advanced solid tumor |
| NCT00944463 | Completed | Gemcitabine/Simvastatin | II | Metastatic or unresectable pancreatic adenocarcinoma |
| NCT03889795 | Recruiting | Metformin/Simvastatin/Digoxin | I | Advanced pancreatic cancer/Advanced solid tumor |
| NCT01488513 | Completed | ABC294640 | I | Pancreatic cancer/Unspecified adult solid tumor |
| Target: Amino acid metabolism | ||||
| NCT01523808 | Completed | GRASPA | I | Locally advanced and non-resectable or metastatic pancreatic adenocarcinoma |
| NCT02195180 | Completed | ERY001/Gemcitabine/Folfox | I | Advanced or metastatic exocrine pancreatic adenocarcinoma |
| NCT02077881 | Completed | Nab-Paclitaxel/Gemcitabine/Indoximod | I/II | Metastatic pancreatic cancer |
| NCT03006302 | Recruiting | Epacadostat/Pembrolizumab/Cyclophosphamide/GVAX | II | Metastatic pancreatic adenocarcinoma |